YOLFTbeta
Entera Bio Ltd

Entera Bio Ltd

ENTX · NASDAQ · Healthcare / Biotechnology

3.11USD-0.11 (-3.42%)

Price History

Full chart

Market Stats

Previous Close3.22
Open3.22
Day Range3.08 – 3.27
52-Week Range0.91 – 4.20
Volume155.35K
Market Cap475.27M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.35
Dividend Yield0.00%
Beta1.39
50-Day Avg2.86
200-Day Avg1.78

About

Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures. The company is also involved in the development of EB612, a tablet peptide replacement therapy, which is in Phase I clinical trial for the treatment of hypoparathyroidism; EB618, a GLP-1/glucagon dual agonist peptide, which is in Phase I clinical trial for the treatment of obesity, metabolic, and fibrotic disorders; and GLP-2 which is in Phase I clinical trial for the treatment of short bowel syndrome and disorders related to mucosal inflammation and nutrient malabsorption. It has a collaboration agreement with OPKO Biologics, Inc for the preclinical and clinical development of LA-PTH and oral dual agonist GLP-1/glucagon peptide. The company was incorporated in 2009 and is based in Jerusalem, Israel.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMs. Miranda J. Toledano M.B.A.
  • Employees20
  • HeadquartersKiryat Hadassah Minrav Building, Jerusalem, Israel, 9112002, USA
  • Websitehttps://enterabio.com

Leadership

  • Ms. Miranda J. Toledano M.B.A.CEO & Director · b. 1977
  • Dr. Hillel Galitzer M.B.A., Ph.D.Chief Operating Officer · b. 1978
  • Dr. Gregory Burshtein Ph.D.Chief of Research & Development · b. 1977
  • Ms. Dana Yaacov-Garbeli CPAChief Financial Officer · b. 1983
  • Dr. Rachel B. WagmanChief Clinical Advisor
  • Ms. Cherin SmithExecutive VP & Head of Clinical Operations
  • Dr. Constantin Itin Ph.D., R.Ph.Head of Biopharmaceutics & Bioanalytics
  • Ms. Michele McDermottMD & EVP of Medical Affairs
  • Mr. Riccardo Paolo Camisasca M.D.Chief Medical Officer

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue000500.00K236.00K365.00K571.00K134.00K14.00K181.00K42.00K
Growth (%)-----52.80%+54.66%+56.44%-76.53%-89.55%+1192.86%-76.80%
Cost of Revenue28.00K35.00K43.00K0448.00K209.00K373.00K101.00K56.00K172.00K42.00K
Gross Profit-28.00K-35.00K-43.00K500.00K-212.00K156.00K198.00K33.00K-56.00K9.00K-30.00K
Gross Margin---100.00%-89.83%42.74%34.68%24.63%-400.00%4.97%-71.43%
Operating Expense3.67M5.33M-11.39M11.36M11.24M11.29M12.41M13.05M8.88M9.59M11.50M
Operating Income-3.70M-5.37M11.34M-10.86M-11.45M-11.13M-12.22M-13.02M-8.94M-9.59M-11.53M
Operating Margin----2172.20%-4853.39%-3050.14%-2139.58%-9714.18%-63857.14%-5295.58%-27450.00%
EBITDA-3.67M-5.33M-11.05M-10.81M-10.47M-10.91M-12.16M-12.95M-8.80M-9.48M-11.41M
EBITDA Margin----2161.40%-4437.71%-2988.49%-2130.30%-9666.42%-62885.71%-5238.12%-27164.29%
Net Income-4.28M-1.20M-11.20M-10.30M-10.79M-9.98M-12.19M-13.07M-8.89M-9.54M-11.44M
Net Income Margin----2060.80%-4574.15%-2735.07%-2134.33%-9754.48%-63492.86%-5271.27%-27235.71%
R&D2.12M2.65M2.77M8.52M6.96M6.40M6.77M5.85M4.45M4.50M6.00M
R&D as % of Total Revenue---1703.60%2949.58%1752.88%1185.81%4364.18%31814.29%2485.64%14295.24%
Interest Expense000084.00K1.40M29.00K26.00M---
Interest Expense % of Total Revenue---0.00%35.59%382.19%5.08%19404.48%---

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets2.75M6.29M13.28M13.34M16.70M9.72M25.99M13.13M11.77M9.39M15.99M
Total Liabilities28.43M31.53M44.84M3.23M4.78M2.21M3.42M1.37M1.38M1.31M2.89M
Total Equity-25.69M-25.25M-31.56M10.12M11.92M7.51M22.57M11.75M10.39M8.08M13.10M
Cash1.21M4.16M11.75M7.51M15.22M8.59M24.89M12.31M11.02M8.66M7.11M
Total Debt8.05M14.72M3.89M-299.00K432.00K302.00K91.00K390.00K272.00K490.00K
Net Debt6.85M10.56M-7.85M-7.51M-14.92M-8.16M-24.59M-12.22M-10.63M-8.39M-6.62M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-3.50M-3.14M-4.53M-9.80M-8.92M-10.56M-9.06M-12.50M-7.31M-6.82M-7.37M
Investing Cash Flow-54.00K-1.12M1.00M-4.07M3.95M-53.00K-17.00K-102.00K-17.00K-3.00K-107.00K
Financing Cash Flow4.46M7.22M11.11M9.62M12.65M4.05M25.38M13.00K6.04M4.48M13.71M
Capital Expenditure54.00K41.00K51.00K68.00K40.00K53.00K17.00K47.00K17.00K3.00K107.00K
Free Cash Flow-3.55M-3.18M-4.58M-9.86M-8.96M-10.61M-9.08M-12.55M-7.33M-6.82M-7.48M
FCF to OCF101.55%101.30%101.13%100.69%100.45%100.50%100.19%100.38%100.23%100.04%101.45%

Earnings

Report DateNov 4, 2016Feb 3, 2017May 4, 2017Nov 9, 2017Jan 5, 2018Jun 29, 2018Aug 20, 2018Sep 30, 2018Mar 28, 2019Jun 27, 2019Aug 20, 2019Nov 21, 2019Mar 26, 2020May 21, 2020Aug 20, 2020Nov 19, 2020Mar 18, 2021May 20, 2021Aug 16, 2021Nov 10, 2021Mar 8, 2022May 12, 2022Aug 11, 2022Nov 10, 2022Mar 31, 2023May 5, 2023Aug 11, 2023Nov 14, 2023Mar 8, 2024May 10, 2024Aug 9, 2024Nov 8, 2024Mar 6, 2025May 9, 2025Aug 8, 2025Nov 14, 2025Mar 27, 2026May 8, 2026Aug 7, 2026Nov 13, 2026
EPS Estimate0.000.000.000.000.00-0.08-0.09-0.28-0.35--0.28-0.15-0.19--0.12-0.20-0.14-0.12-0.12-0.11-0.23-0.18-0.16-0.13-0.11-0.12-0.07-0.09-0.08-0.06-0.06-0.05-0.08-0.07-0.11-0.09-0.11-0.08-0.08-0.07
EPS Actual-0.15-0.07-0.13-0.19-0.31-0.08-0.16-0.45-0.17-0.26-0.12-0.25-0.260.16-0.17-0.09-0.13-0.43-0.21-0.05-0.21-0.13-0.11-0.11-0.10-0.08-0.08-0.08-0.07-0.05-0.06-0.08-0.06-0.06-0.06-0.07-0.06-0.07-0.14-
Surprise-----0.00%-77.78%-60.71%51.43%-57.14%-66.67%-36.84%--41.67%55.00%7.14%-258.33%-75.00%54.55%8.70%27.78%31.25%15.38%9.09%33.33%-14.29%11.11%12.50%16.67%0.00%-60.00%25.00%14.29%45.45%22.22%45.45%12.50%-75.00%-
Timing-----After-hoursAfter-hours-Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hours-After-hours-After-hours

Key Statistics & Ratios

Market Cap475.27M
Enterprise Value478.24M
Trailing P/E0.00
Forward P/E0.00
Price / Sales1547.08
Price / Book67.32
EPS-0.35
Book Value0.147
Revenue (TTM)0
Gross Profit (TTM)0
EBITDA-14.37M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-138.92%
Return on Assets-45.98%
Shares Outstanding173.14M
Shares Float126.58M
Beta1.39
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 9.75
  • Buy
    1

Ownership Breakdown

Institutions
34.11%
Insiders
6.85%
Retail / Other
59.04%

Top Institutional Holders

  • Knoll Capital Management LP
    5.88M3.19%
  • Renaissance Technologies Corp
    473.44K0.26%
  • Parkman Healthcare Partners LLC
    274.50K0.15%
  • Seven Fleet Capital Management LP
    205.54K0.11%
  • Marshall Wace Asset Management Ltd
    195.78K0.11%
  • Northern Trust Corp
    146.85K0.08%
  • XTX Topco Ltd
    131.62K0.07%
  • Schonfeld Strategic Advisors LLC
    55.22K0.03%
  • Signature Estate & Investment Advisors
    47.33K0.03%
  • Citadel Advisors Llc
    38.80K0.02%
  • HighTower Advisors, LLC
    36.83K0.02%
  • Jane Street Group LLC
    32.91K0.02%
  • Diadema Partners LP
    23.26K0.01%
  • Geode Capital Management, LLC
    21.14K0.01%
  • Gem Investment Advisors, LLC
    19.14K0.01%
  • HRT FINANCIAL LLC
    15.49K0.01%
  • Point72 Asset Management, L.P.
    12.38K0.01%
  • Bank of America Corp
    12.00K0.01%

Top Fund Holders

  • WEALTHGATE Biotech Fund Inst
    76.56K0.04%
  • Fidelity Nasdaq Composite Index
    29.91K0.02%